NovoCure Limited (NVCR)
(Real Time Quote from BATS)
$17.87 USD
-0.03 (-0.17%)
Updated Aug 19, 2024 03:40 PM ET
2-Buy of 5 2
D Value C Growth A Momentum C VGM
NovoCure (NVCR) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$25.71 | $40.00 | $18.00 | 43.63% |
Price Target
Based on short-term price targets offered by seven analysts, the average price target for NovoCure comes to $25.71. The forecasts range from a low of $18.00 to a high of $40.00. The average price target represents an increase of 43.63% from the last closing price of $17.90.
Analyst Price Targets (7 )
Broker Rating
NovoCure currently has an average brokerage recommendation (ABR) of 2.14 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 2.14 a month ago based on seven recommendations.
Of the seven recommendations deriving the current ABR, three are Strong Buy, representing 42.86% of all recommendations. A month ago, Strong Buy represented 42.86%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/NVCR.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 4 | 4 | 4 | 4 | 4 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.14 | 2.14 | 2.14 | 2.14 | 2.14 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/26/2024 | Wells Fargo Securities | Lawrence H Biegelsen | Strong Buy | Strong Buy |
7/26/2024 | H.C. Wainwright & Co. | Emily Bodnar | Hold | Hold |
7/25/2024 | SVB Securities | Jonathan W Chang | Strong Buy | Strong Buy |
7/25/2024 | Wedbush Securities | David M Nierengarten | Hold | Hold |
7/2/2024 | Evercore Partners | Vijay Kumar | Hold | Hold |
5/2/2024 | Piper Sandler | Jason Bednar | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.14 |
ABR (Last week) | 2.14 |
# of Recs in ABR | 7 |
Average Target Price | $25.71 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 70 of 253 |
Current Quarter EPS Est: | -0.34 |